Skip to content

A Clinical study to compare two Ayurvedic treatments in patients with sciatica

A Randomized Comparative Clinical Trial to Evaluate the Effect of Mridu Virechana over Vaitarana Vasti in the management of Vata-Kaphaja Gridhrasi - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/03/105592
Enrollment
50
Registered
2026-03-09
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M511- Thoracic, thoracolumbar and lumbosacral intervertebral disc disorders with radiculopathy

Interventions

None listed

Sponsors

Sreedev A S
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Participants with signs and symptoms of Vata-Kaphaja Gridhrasi Participants having radiating pain in either legs Participants with positive SLR/Lasegue signs/Bragards test Participants fulfilling ICD-10 code:M54.3 Participants fit for Vasti/Virechana Consent Provided Raised ESR/HsCRP

Exclusion criteria

Exclusion criteria: Pregnancy/Lactation History of spinal surgery and vertebral fracture congenital spinal anomalies TB spine Osteomyelitis Malignancies Ankylosing spondylosis Systemic uncontrolled disease like uncontrolled diabetes Unfit for Vasti/Virechana

Design outcomes

Primary

MeasureTime frame
Reduction in pain intensity assessed by visual analogue scale improvement in functional disability assessed by Oswestry disability index assesments will be performed at baseline(Day 0),post treatment(Day 6) and follow up(day 30)Timepoint: baseline(Day 0),post treatment(Day 6) and follow up(day 30)

Secondary

MeasureTime frame
Secondary outcomes include improvement in neurological signs (SLR, Lasegue s sign, Bragard s test), reduction in classical Ayurvedic symptoms, improvement in functional mobility parameters, & reduction in inflammatory markers (ESR & HsCRP).Timepoint: Assessments will be performed at baseline (Day 0), post-treatment (Day 6), & follow-up (Day 30). Inflammatory markers will be assessed at baseline(Day 0) & post-treatment(Day 6).

Countries

India

Contacts

Public ContactSREEDEV A S

Vishnu Ayurveda College

jc251175@gmail.com9599874855

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026